|Articles|September 2, 2014
Applied Clinical Trials Editorial Advisory Board and Clinical Trials Professionals Discuss Importance of DIA
Advertisement
Nancy Dreyer, PhD, MPH, FISPe, discusses the importance of DIA to the industry.
Stewart Geary, MD, discusses how global drug development benefits from DIA.
Michael R. Hamrell, PhD, discusses the impact of DIA on professional development.
Moe Alsumidae discusses how DIA's neutral platform grows industry collaboration and communication.
Tim Callahan, PhD, discusses the scientific benefit of DIA
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
5